Welcome to D&H National Research Centers, where we invite you to participate in groundbreaking research to improve the lives of individuals with psoriasis and get up $1200 Compensation.
Psoriasis is a chronic autoimmune condition that affects the skin, causing an accelerated buildup of skin cells. This rapid turnover leads to the formation of raised, red patches topped with silvery scales, often accompanied by itching and discomfort.
Are you or a loved one suffering from Psoriasis? If so, you may be interested in participating in our clinical trial. In D&H National Research Centers we recognize the challenges faced by individuals living with psoriasis. That's why we're conducting a groundbreaking medical trial aimed at advancing treatment options for this condition.
Psoriasis can significantly impact one's quality of life, both physically and emotionally. Our trial seeks to explore innovative treatments that could alleviate symptoms and improve daily living for those affected. By participating, you'll contribute directly to pioneering research in the field of dermatology.
Our trial is designed to:
Access to innovative treatments: By participating in our clinical trial, you will have the opportunity to receive cutting-edge treatments that could potentially improve your Psoriasis symptoms and overall quality of life.
Expert medical care: The D&H National Research Centers team of healthcare professionals and researchers will closely monitor your progress throughout the trial, ensuring that you receive the highest standard of care and support.
Contribution to medical research: Your participation directly impacts the future of psoriasis treatment..
Compensation: Receive $700 compensation for your time, dedication.and travel expenses up $1200.
D&H National Research Centers is currently conducting a study on Psoriasis. As a prominent leader in clinical research in Florida, we are committed to advancing medical knowledge and patient care.
If you want to participate in this study, you must meet the following criteria:
Male or female subjects aged from 18 to 75 years old (both inclusive).
Have had a diagnosis of moderate-to-severe Psoriasis for at least 6 months prior to Baseline.
Participants with moderate-to-severe Plaque Psoriasis covering ≥10% body surface area.
Participants with plaque psoriasis who are systemic treatment naïve or have received at least one of the conventional anti-psoriasis treatments such as acitretin, phototherapy, methotrexate, cyclosporine, apremilast, or biologic therapy.
You are not eligible for participation in this study if:
Pregnant or nursing women.
Past history of gastrointestinal perforation, history of peptic ulcers and/or regular use of NSAIDs.
History of chronic alcohol or drug abuse within 6 months prior to Screening as determined by the Investigator based on medical history and patient interview.
Current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, neurologic, or psychiatric disease.
Subject is currently being treated with or has received strong cytochrome P450 3A
(CYP3A4) inhibitors, such as itraconazole, within 4 weeks prior to Baseline (Day 0).
D&H National Research Centers is a leading medical trial center located in Florida.
If you are interested in joining our Plaque Psoriasis medical trial or have questions about the study, please don't hesitate to reach out to us. We are here to provide you with all the information and support you need, please fill the form or contact us by phone: (786) 375-6210